Charles Q. Morris was named Chief Medical Officer of Prelude Therapeutics Inc, effective April 20, 2026. As of November 6, 2026, Prelude Therapeutics Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 15, 2026, naming 1 appointment (Form 8-K, April 15, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Prelude Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Prelude Therapeutics Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-15. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Prelude Therapeutics Inc files it.
Also on the record for Prelude Therapeutics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 8, 2026 | Stake report, Schedule 13G, by Soleus Capital Management, L.P. | 5.2% of the class | 5%+ stakes | Source |
| April 28, 2026 | Stake report, Schedule 13G, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| April 23, 2026 | Stake report, Schedule 13D/A, by ORBIMED ADVISORS LLC | 16% of the class | 5%+ stakes | Source |
| April 22, 2026 | Stake report, Schedule 13D/A, by Baker Bros. Advisors LP | 15.5% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Vaddi Krishna | 13.15% of the class | 5%+ stakes | Source |
| November 7, 2025 | Stake report, Schedule 13G, by INCYTE CORP | 9.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Prelude Therapeutics Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Prelude Therapeutics Inc and the records around it.
Prelude Therapeutics Inc elsewhere on the record
- 5%+ stake filings Jul 2026
- Who owns it
Companies that share a holder
- Soleus Private Equity Fund III, L.P. also filed stake reports on 5 other companies: CALCIMEDICA, INC. (May 2026), Aprea Therapeutics, Inc. (Apr 2026), INVIVYD, INC. (Feb 2026)
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
- ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)
Watch Prelude Therapeutics Inc
Get an email when Prelude Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Prelude Therapeutics Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Prelude Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Prelude Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-15 | In | Chief Medical Officer | 2026-04-20 | 8-K, 2026-04-15 |
Who leads Prelude Therapeutics Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Medical Officer: Charles Q. Morris, appointed, effective 2026-04-20 (filed 2026-04-15).
New leaders reset buying decisions — get the Full Report on Prelude Therapeutics Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Medical Officer at Prelude Therapeutics Inc, with the record behind each one.
Find candidates like Chief Medical Officer at Prelude Therapeutics IncEvery change, in the filing's words
Appointed: Charles Q. Morris, Chief Medical Officer, effective 2026-04-20
(c) On April 15, 2026 Prelude Therapeutics Incorporated, (the " Company ") announced that the Board of Directors of the Company (the " Board ") appointed Charles Q. Morris, M.D., age 61, as the Chief Medical Officer of the Company, effective on April 20, 2026 (the " Appointment Date ").
- Prior to joining the Company, Dr. Morris served as Chief Medical Officer at Lava Therapeutics N.V. from February 2023 until its acquisition by XOMA Royalty in October 2025.
- Previously, he was Chief Medical Officer at Celyad Oncology from April 2021 to January 2023 and Radius Health from September 2018 to December 2020.
- Dr. Morris received his Degrees of Bachelor of Medicine and Bachelor of Surgery from Sheffield University Medical School, a Bachelor of Medical Science in Clinical Pharmacology and Therapeutics from Sheffield University Medical School, and is a Member of the Royal College of Physicians of London.
- Additionally, in the event Dr. Morris experiences a termination of his employment without "Cause" or he resigns for "Good Reason" (each as defined in the Employment Agreement), provided that he executes and makes effective a release of claims against the Company and its affiliates, Dr. Morris will become entitled to (i) continued base salary for nine months, payable in accordance with the Company's standard payroll practices and (ii) premium payments for continued healthcare coverage for up to nine months.
Tools for this story
Each opens in a new tab, filled in for Prelude Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.